

Updates on Urothelial Carcinoma
Live Virtual Course | Date: September 6, 2024

Premier Sponsor



Friday, September 6, 2024		
Time (Mountain Time)	Topic	Presenter(s)
8:00-8:15 am	Welcome and Introductions	<i>Dr. Christine Mullin, Dr. Zachary Wright</i>
8:15-8:45 am	Lapatinib Therapy in Canine Urothelial Carcinoma: From Molecular Insights to Clinical Outcomes <ul style="list-style-type: none"> • Role of HER2 in canine urothelial carcinoma • Molecular mechanisms of antitumor effects in lapatinib • Efficacy of lapatinib in canine urothelial carcinoma • Adverse events of lapatinib in dogs 	<i>Dr. Shingo Maeda</i>
8:45-9:45 am	Advances in Urothelial Carcinoma <ul style="list-style-type: none"> • Have a broad knowledge of canine invasive urothelial carcinoma. • Know avoidable risk factors for the cancer. • Understand the benefit of early detection and early intervention. 	<i>Dr. Debbie Knapp</i>
9:45-10:00 am	Break	
10:00-11:00 am	KEYNOTE: Novel Therapeutic Approaches in Advanced Bladder Cancer: Potential Opportunities for Veterinary Translation	<i>Dr. Jonathan Rosenberg</i>
11:00 am-12:00 pm	Panel Discussion on Morning Topics	<i>Dr. Jonathan Rosenberg Dr. Debbie Knapp Moderator: Zachary Wright</i>

Updates on Urothelial Carcinoma
Live Virtual Course | Date: September 6, 2024

Premier Sponsor



Friday, September 6, 2024		
Time (Mountain Time)	Topic	Presenter(s)
12:00-12:30 pm	Lunch Break	
12:30 – 1:00 pm	<p>Lunch & Learn – Presented by Nutramax The Science behind Avmaquin, a Sulforaphane-Producing Supplement with Potential Clinical Applications</p> <ul style="list-style-type: none"> • Upon completion of this session/learning activity, participants will be introduced to (gain knowledge of) the following concepts: • What is sulforaphane and how is it produced? • The molecular mechanisms of sulforaphane • The development of Avmaquin, a sulforaphane-producing dietary supplement for companion animals • Sulforaphane clinical trials in humans and companion animals • Potential clinical applications 	<i>Dr. Nikki Harris Wiezbiski</i>
1:00-1:30 pm	<p>Radiotherapeutic Approaches to Canine Urothelial Carcinoma</p> <ul style="list-style-type: none"> • Understand the role of low intensity palliative intent radiotherapy for management of canine urothelial carcinoma; be able to describe commonly used treatment protocols and associated clinical outcomes. • Understand the role of radiotherapy in a definitive-intent multimodal treatment approach for canine urothelial carcinoma. Be able to describe how radiotherapy is prescribed in this setting, and how it can be interfaced with other standard therapies such as chemotherapy and surgery. 	<i>Dr. Mike Nolan</i>
1:30-2:00 pm	<p>Novel Lower Urinary Tract Interventional Oncology Options</p> <ul style="list-style-type: none"> • Attendees will learn how intra-arterial chemotherapy is performed and what outcomes have been achieved. • Current results of prostatic artery embolization will be discussed as will major complications. • Ablation will be explained and applications in urinary tract disease will be discussed. 	<i>Dr. William Culp</i>
2:00-2:15 pm	Break	

Updates on Urothelial Carcinoma
Live Virtual Course | Date: September 6, 2024

Premier Sponsor



Friday, September 6, 2024		
Time (Mountain Time)	Topic	Presenter(s)
2:15-2:45 pm	<p>Updates on Surgical Treatment Options for Urothelial Carcinoma</p> <ul style="list-style-type: none"> List the surgical treatment options for urothelial carcinoma of the bladder and prostate. Relate the patient selection criteria for partial cystectomy, total cystectomy, and prostatectomy for urothelial carcinoma. Discuss the complications and expected outcomes for partial cystectomy, total cystectomy, and prostatectomy for urothelial carcinoma. 	<i>Dr. Laura Selmic</i>
2:45-3:15 pm	<p>Cystoscopic Ablation of Urothelial Carcinoma</p> <ul style="list-style-type: none"> At the end of this lecture, attendees will be able to Identify suitable candidates for cystoscopic ablation of urothelial carcinoma Compare cystoscopic ablation with other approaches such as urethral stent placement Incorporate cystoscopic ablation into management protocols for patients with urothelial carcinoma 	<i>Dr. Audrey Cook</i>
3:15-4:15 pm	Panel Discussion on Afternoon Topics	<p><i>Dr. Mike Nolan, Dr. William Culp, Dr. Laura Selmic, Dr. Audrey Cook</i></p> <p><i>Moderator: Christine Mullin</i></p>
4:15-4:30 pm	Closing Remarks	<i>Dr. Christine Mullin</i>